2,460,987 Shares in DaVita Inc. $DVA Purchased by BlackRock Inc.

Key Points

• BlackRock acquired 2.46 million DaVita shares during the second quarter, worth approximately $547.5 million and representing about 3.86% of the company. Institutional investors collectively own 90.12% of DaVita.
• DaVita exceeded quarterly expectations, reporting $4.02 in EPS versus the $3.88 estimate and $3.55 billion in revenue, up 5.2% year over year. The company issued fiscal 2026 EPS guidance of $14.10–$15.20.
• Analyst sentiment remains mixed but improved, with several firms upgrading DaVita or raising price targets; the consensus rating is Hold with an average price target of $221.75.

BlackRock Inc. purchased a new position in DaVita Inc. (NYSE:DVA - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 2,460,987 shares of the company's stock, valued at approximately $547,520,000. BlackRock Inc. owned approximately 3.86% of DaVita as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of DVA. Performance Wealth Partners LLC purchased a new stake in DaVita during the second quarter valued at approximately $667,000. Deutsche Bank AG bought a new position in shares of DaVita during the second quarter worth $46,356,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in DaVita during the second quarter valued at $8,835,000. Beverly Hills Private Wealth LLC bought a new stake in DaVita in the 2nd quarter worth approximately $263,000. Finally, Plato Investment Management Ltd purchased a new stake in shares of DaVita during the 2nd quarter worth approximately $87,000. 90.12% of the stock is currently owned by institutional investors.

Insider Activity

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the sale, the insider directly owned 109,194 shares in the company, valued at $22,756,029.60. This represents a 12.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.90% of the company's stock.

DaVita Stock Up 1.6%

NYSE:DVA opened at $176.53 on Tuesday. DaVita Inc. has a 52 week low of $101.00 and a 52 week high of $247.49. The stock's 50-day moving average price is $214.30 and its 200-day moving average price is $182.32. The stock has a market capitalization of $11.26 billion, a PE ratio of 14.45, a price-to-earnings-growth ratio of 0.58 and a beta of 0.88.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating analysts' consensus estimates of $3.88 by $0.14. The firm had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. DaVita's quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the company posted $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Sell-side analysts expect that DaVita Inc. will post 14.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Weiss Ratings upgraded DaVita from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Wednesday, August 5th. Oppenheimer set a $220.00 target price on DaVita in a research report on Friday, August 7th. Barclays upped their price objective on shares of DaVita from $218.00 to $224.00 and gave the company an "equal weight" rating in a report on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and set a $265.00 target price on shares of DaVita in a report on Wednesday, August 5th. Finally, TD Cowen raised DaVita from a "hold" rating to a "buy" rating and boosted their price objective for the company from $201.00 to $220.00 in a report on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, DaVita currently has a consensus rating of "Hold" and an average price target of $221.75.

DaVita Company Profile

DaVita Inc NYSE: DVA is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source